NCT07033494

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 340 (estimated)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Conditions

• Early Alzheimer's Disease

Interventions

Type	Name	Description
BIOLOGICAL	MK-2214	IV infusion
DRUG	Placebo	IV infusion

Timeline

• Start date: 2025-07-16
• Primary completion: 2029-04-30
• Completion: 2029-04-30
• First posted: 2025-06-24
• Last updated: 2026-04-17

Locations

71 sites across 9 countries: United States, Argentina, Australia, Belgium, Japan, Netherlands, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study